Вячеслав Миколайович Ждан, Вячеслав Николаевич Ждан, Vm Zhdan

Вячеслав Миколайович Ждан, Вячеслав Николаевич Ждан, Vm Zhdan

Poltava State Medical University - Poltava / Ukraine
Others
AD Scientific Index ID: 5291204
Полтавський державний медичний університет
person_outline Вячеслав Миколайович Ждан, Вячеслав Николаевич Ждан, Vm Zhdan's MOST POPULAR ARTICLES
1-) A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy P Emery, J Vencovský, A Sylwestrzak, P Leszczyński, W Porawska, ... Annals of the rheumatic diseases 76 (1), 51-57, 2017 2792017
2-) Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial S Cohen, K Tuckwell, TR Katsumoto, R Zhao, J Galanter, C Lee, J Rae, ... Arthritis & Rheumatology 72 (9), 1435-1446, 2020 922020
3-) Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trialsDT Rubin, I Dotan, A DuVall, Y Bouhnik, G Radford-Smith, PDR Higgins, ...The lancet Gastroenterology & hepatology 7 (1), 17-27, 2022872022
4-) 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritisP Emery, J Vencovský, A Sylwestrzak, P Leszczyński, W Porawska, ...Rheumatology 56 (12), 2093-2101, 2017872017
5-) Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 studyS Vermeire, PL Lakatos, T Ritter, S Hanauer, B Bressler, R Khanna, ...The Lancet Gastroenterology & Hepatology 7 (1), 28-37, 2022692022